When we considered the change in adiponectin levels between baseline and 12 months, we observed a higher proportion of breast cancer cases in subjects with a decrease in adiponectin than in subjects with an increase in adiponectin (38.2% vs. 25.9%, p = 0.04). This evidence concerns the gene ADIPOQ and breast cancer.